Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With <scp>BRAFV600</scp> Mutant Melanoma: Implications for Combination With Immunotherapy
Data from this study provides provocative evidence that, while BRAF+/-MEK inhibitor therapy produces an increase in overall and clonal T cell infiltrates, there is limited evidence for generation of new or persistent tumor immunity. Thus, BRAFi/MEKi therapy may enable tumor-reactive T cells to infiltrate tumors but tumor control does not appear to depend on priming new immune responses.
Authors
- Christine Tran (ORCID: https://orcid.org/0000-0003-0226-6374)
- Ileana Soto Mauldin (ORCID: https://orcid.org/0000-0002-9318-8342)
- Jia‐Ren Lin
- Geoffrey T. Gibney (ORCID: https://orcid.org/0000-0002-5401-8498)
- Gabrielle Schwartzman (ORCID: https://orcid.org/0000-0002-3912-5527)
- Benjamin Izar
- R. Sullivan
- M.B. Atkins
- Craig L. Slingluff
- Jennifer A. Wargo
- Waddah Al‐Refaie
- Suthee Rapisuwon
- Walter C. Olson
Institutions
- Creighton University (US)
- The University of Texas MD Anderson Cancer Center (US)
- Georgetown University (US)
- Columbia University Irving Medical Center (US)
- Georgetown University Medical Center (US)
- Massachusetts General Hospital (US)
- Center for Systems Biology (US)
- University of Virginia Cancer Center
- University of Virginia (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2026-01-01
- DOI
- https://doi.org/10.1002/cam4.71526
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Melanoma Research Alliance
- Ohio State University
- Georgetown University
- Regeneron Pharmaceuticals
- Celldex Therapeutics
- Eisai
- Institut Gustave-Roussy
- Genentech
- University of Texas MD Anderson Cancer Center
- Lombardi Comprehensive Cancer Center, Georgetown University
- University of Toronto Scarborough
- Janssen Pharmaceuticals